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Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis char-
acterized by infiltrates of lipid-laden CD68þ/CD1a histiocytes, affecting heart,
lungs, central nervous system, and bones. Kidney and adjacent structures can also
be affected, leading to renal failure in about 30% of cases. The diagnosis is
challenging, and treatment is generally based on administration of interferon-
alpha (IFNα), but preliminary results also showed the therapeutic efficacy of
anakinra, an antagonist of the receptor of interleukin-1 (IL-1). We report the case
of an elderly patient with ECD and severe involvement of the heart and kidneys who
was successfully treated with anakinra.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Erdheim-Chester disease (ECD) is a rare non-Langerhans
cell histiocytosis that affects multiple organ and systems. Since
the first description by Chester in 1930, approximately 450
cases have been reported in international literature. The
disease is characterized by xanthogranulomatous infiltrates
of foamy CD68þ/CD1a histiocytes usually surrounded by
fibrosis. The etiology and pathogenesis of ECD remain poorly
understood and its classification as a tumoral or inflammatory
disease is controversial [1].
The clinical presentation is variable. A single patient may
have a different combination of symptoms depending on the
organs involved. Commonly involved sites are retro-orbital
soft tissue, pituitary gland, lungs, and central nervous system,
with manifestation ranging from diabetes insipidus to cere-
bellar or pyramidal syndromes, cognitive impairment andn Society of Nephrology. Publi
c-nd/4.0/).
itas, Istituto di Ricovero e
oni 56, 20089 Rozzano –
(G Graziani).cranial nerve paralysis. Infiltration of the liver, spleen, thyroid,
skin, conjunctiva, and false vocal cord may also occur [1]. The
involvement of flat and long bones is almost universal and
causes juxta-articular pain, mainly in the knees and ankles.
Cardiovascular symptoms may also occur: they are mainly
related to pericardial effusion, which bears a high risk of
cardiac tamponade. Less commonly, myocardial infiltration
may cause a typical pattern of “pseudo-tumor”, usually loca-
lized in the right heart. Myocardial infarctions and valvular
heart disease have also been reported [2]. Kidneys may be
involved in up to 30% of cases [1]; renal disease may be caused
by a direct invasion of the renal sinus and parenchyma or by a
distal ureteral obstruction. In some cases, a periaortic infiltra-
tion extends to the renal vessels and spreads to the perirenal
and hilar region of the kidneys, resulting in bilateral hydrone-
phrosis or in renal artery compression, renovascular hyperten-
sion, and kidney ischemic injury, or in ureteral compression
and bilateral hydronephrosis. Interestingly, both the vena cava
and the pelvic ureters are usually unaffected, a feature that
helps to distinguish ECD from retroperitoneal fibrosis. Kidney
involvement is rarely symptomatic, but it may be progressive
and lead to end-stage renal disease [3].shed by Elsevier. This is an open access article under the CC BY-NC-ND
Kidney Res Clin Pract 33 (2014) 165–167166Prior to the introduction of interferon-alpha (IFNα), the
mortality in patients with ECD was as high as 60% within 32
months from clinical diagnosis. Treatment with high-dose IFNα
improved prognosis in about 67% of patients [4], but myocar-
dial, renal, pulmonary, or central nervous system complications
remain a frequent cause of death. Recently, encouraging results
have been reported with anakinra, the recombinant form of
interleukin-1 (IL-1) receptor antagonist [5–7]. We report here
the beneficial results of anakinra in an elderly patient affected
by ECD with kidney, heart, and bone involvement.Case report
A 76-year old man was admitted to our unit because of
hypertension and renal function deterioration. His medical
history was remarkable for chronic kidney disease with a
baseline creatinine of 1.6 mg/dL, diabetes mellitus type 2,
transient ischemic attacks, coronary artery disease, and recur-
rent episodes of colicky pain due to kidney stones.
At presentation, the patient complained of asthenia, per-
manent bone pain, dull chest pain, and dyspnea. Blood
pressure was 150/80 mmHg. Physical examination of the
lungs, heart, and abdomen was unremarkable. Laboratory
investigations showed: serum creatinine 2.6 mg/dL, phosphate
5.2 mg/dL, and glycated hemoglobin 7.2%. All of the other tests,
including complete blood count, electrolytes, and urinalysis,
were normal.
Urinary tract ultrasonography showed bilateral hydrone-
phrosis with a stone measuring 10 mm in diameter in the right
kidney. Contrast-enhanced computed tomography also
revealed the presence of an extrapelvic fibrous tissue which
extended up to the ureteral origin, determining a significant
bilateral constriction and stretching of the renal pelvis, with
retrodilation of the calyces. The ureters were not dilated. At
magnetic resonance imaging (MRI), the extrapelvic tissue
signal was compatible with the presence of fibrous tissue
(Fig. 1). A laparotomy biopsy of the perirenal area showed a
fibromuscular tissue diffusely infiltrated by foamy histiocytes,
along with areas of steatonecrosis. On direct immunofluores-
cence, the histiocytes were CD68þ and CD1a .
A cardiac MRI showed pericardial effusion and a mass
infiltrating the interatrial septum, which extended up to theFigure 1. Abdominal T2-weighted magnetic resonance imaging showing
the renal pelvis, with retrodilation of the calyces (A: axial plane, B: corojunction of the cava veins. The mass signal was not homo-
geneous, with punctiform nodulations, strongly suggesting a
diagnosis of histiocytosis. A bone X-ray showed medullary
osteosclerosis. Tests for lung and cerebral involvement were
negative.
A diagnosis of ECD was made and treatment with subcuta-
neous pegylated IFNαwas started at a dose of 180 mg/wk, which
was afterwards reduced to 135 mg/wk. Heart MRI at 12 months
showed reduction of the pericardial effusion and decrease of
the right atrium wall thickening from 18 cm to 9 cm. However,
treatment was poorly tolerated because of weakness, edema,
and hypotension. Of more concern, serum creatinine progres-
sively increased up to 3.9 mg/dL. IFNα was withdrawn, and
subcutaneous anakinra (100 mg/d, according to the technical
schedule) was started. After 1 year of therapy, the symptoms
improved, serum creatinine decreased to 2.0 mg/dL, and a
follow-up ultrasound showed the absence of hydronephrosis.
After another year of follow-up, serum creatinine was still
stable at around 2.0 mg/dL.Discussion
ECD is an exceptionally rare disease that eventually leads to
a multifaceted clinical presentation. The diagnosis and treat-
ment are difficult. When the histiocytic xanthogranulomatous
infiltrates invade the perirenal and hilar tissues, a number of
consequences may occur, ranging from progressive parenchy-
mal ischemia and renal artery stenosis to ureteral obstruction
and hydronephrosis. These lesions may eventually lead to
chronic renal failure.
Attempts to treat ECD have been based on glucocorticoids
associated with bisphosphonates and/or cytotoxic drugs, or
high-dose chemotherapy followed by peripheral autologous
hematopoietic stem cell transplantation. Braiteh et al [8]
reported the first successful treatment with IFNα in three
patients with advanced ECD. It has been suggested that IFNα
may activate CD40-ligand, a member of the tumor necrosis
factor (TNF) superfamily which binds to CD40 on dendritic
cells. CD40-ligand accelerates the maturation of dendritic cells,
and favors immune-mediated destruction of histiocytes. More-
over, IFNα has an immunomodulatory effect and antiinflam-
matory action by reducing lesional histiocyte recruitment.the extrapelvic fibrous tissue determining a bilateral constriction of
nal plane).
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the organs involved [6]. In our patient, IFNα obtained an
important reduction of myocardial pseudotumoral mass and
pericardial effusion. However, renal function progressively
deteriorated over time, with creatinine up to 3.9 mg/dL.
Therapeutic dose is another open issue. Some authors reported
that only high doses of IFNα could obtain a significant
improvement of symptoms in about 66% of patients, but half
of them complained of side effects [4]. Other investigators
suggested that the initial dose of 3.0–6.0106 units, three
times/wk, given subcutaneously, may be safely reduced to
1.0 106 units in the long-term, to avoid side effects such as
fatigue and flu-like syndrome [9]. However, in our patient,
adverse events did not subside, even after dose adjustment.
Previous studies in ECD patients reported increased levels
of proinflammatory cytokines, such as IL-1 and TNFα. More
recently, Arnaud et al [10] found a significant increase in
plasma levels of IL-6, a proinflammatory cytokine induced by
T helpher (Th)1 responses, along with an increase of IL-12,
which favors the Th1 pathway [10]. These data suggest that
ECD is associated with a systemic immune Th1-oriented
disorder. In this setting, novel therapeutic approaches may
be based on drugs that prevent the biologic activity of
proinflammatory cytokines, particularly IL-1. Anakinra is a
recombinant, non-glycosylated form of human IL-1 receptor
antagonist (IL-1Ra), which binds to IL-1 membrane receptor
and downregulates the biologic activities of IL-1, including
inflammation. This effect is similar to that exerted by IFNα,
which in fact increases the expression of IL-1Ra. Aouba et al [5]
first reported a significant reduction of IL-1α (a form expressed
at the monocytes membrane surface after cell stimulation)
following treatment with 100 mg/d of anakinra, a finding that,
along with clinical improvement, supported the hypothesis of
IL-1 as a primary actor in ECD systemic perturbation. Anakinra
also showed important results in some ECD patients with
skeletal [6] and cardiac involvement [7]. In all cases, a reduc-
tion of inflammatory markers, fever, and ECD symptoms was
observed.
According to the technical schedule, anakinra should not be
administered to patients with severe renal failure (creatinine
clearance o30 mL/min/1.73m2) and should be used with
caution in geriatric patients. Despite this, we decided to use
anakinra as a rescue therapy in our patient, because of the
poor tolerance of IFNα and the progressive deterioration of
kidney function. We closely monitored possible side effects
related to drug administration, such as infections and neutro-
penia. General conditions of the patient improved and plasma
creatinine reduced from 3.9 mg/dL to 2.0 mg/dL. Neither renal
artery nor ureteral stenting were necessary to obtain this
result. Moreover, in contrast to IFNα therapy, which causedsevere side effects, anakinra was well tolerated with no
side effects, even in the long-term. To the best of our knowl-
edge, this is the first reported case of ECD with renal
failure, unresponsive to IFNα therapy, successfully treated with
anakinra.Conflict of interest
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